Astrana Health (ASTH) saw its stock plummet 12.05% in intraday trading on Friday, following the company's disappointing fourth-quarter 2024 results and lackluster guidance for 2025.
Despite an 88.4% year-over-year increase in revenue to $665.21 million, the healthcare provider missed Wall Street's expectations. The company reported an adjusted loss of $0.15 per share, falling short of analysts' estimates of $0.12 earnings per share.
Astrana Health's outlook for 2025 also failed to impress investors. The company forecasted revenue in the range of $2.5 billion to $2.7 billion and adjusted EBITDA of $170 million to $190 million, both lower than analysts' projections. The weaker guidance was attributed to headwinds from higher-than-expected Medicaid trends and costs associated with strategic investments in integration, automation, and AI.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。